Albinterferon alfa-2b
Albinterferon alfa-2b is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
383 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 3 | 28 | 31 | 26 | 14 | 97 |
| Hepatitis c | D006526 | — | B19.2 | 6 | 18 | 21 | 13 | 6 | 58 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 12 | 14 | 6 | 2 | 3 | 33 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 5 | 9 | 11 | 5 | 7 | 32 |
| Neoplasms | D009369 | — | C80 | 8 | 5 | — | 1 | — | 13 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | 4 | 1 | 3 | 8 |
| Hepacivirus | D016174 | — | — | — | 4 | 3 | 1 | 1 | 8 |
| Hepatitis b | D006509 | — | — | — | 2 | 2 | 1 | 3 | 8 |
| Hiv | D006678 | — | O98.7 | 1 | 1 | — | 2 | — | 4 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | 2 | — | 1 | 1 | 4 |
Show 11 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 13 | 14 | 9 | — | 1 | 35 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | 12 | 3 | — | 1 | 16 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | 6 | 5 | — | — | 10 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | 5 | 1 | — | — | 7 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | 2 | 2 | — | 1 | 5 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 2 | 2 | — | 1 | 5 |
| Polycythemia vera | D011087 | — | D45 | — | 1 | 3 | — | — | 4 |
| Covid-19 | D000086382 | — | U07.1 | 2 | 3 | 1 | — | — | 3 |
| Multiple myeloma | D009101 | — | C90.0 | — | 1 | 2 | — | — | 3 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | 2 | — | — | 3 |
Show 20 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 3 | — | — | — | 5 |
| Kaposi sarcoma | D012514 | — | C46 | 3 | 2 | — | — | — | 5 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 4 | — | — | — | 4 |
| Leukemia | D007938 | — | C95 | 2 | 1 | — | — | 1 | 3 |
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | — | — | — | 2 |
| Adenocarcinoma | D000230 | — | — | — | 2 | — | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | — | 2 | — | — | — | 2 |
| Essential thrombocythemia | D013920 | — | D47.3 | — | 2 | — | — | — | 2 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | — | 1 | — | — | 1 | 2 |
| Uveal neoplasms | D014604 | EFO_1001230 | — | — | 2 | — | — | — | 2 |
Show 21 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | 1 | 4 |
| Triple negative breast neoplasms | D064726 | — | — | 2 | — | — | — | — | 2 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
| Anus neoplasms | D001005 | EFO_0003835 | C21 | 1 | — | — | — | — | 1 |
| Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intravenous substance abuse | D015819 | — | — | — | — | — | — | 1 | 1 |
| Lipodystrophy | D008060 | HP_0009125 | E88.1 | — | — | — | — | 1 | 1 |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | — | — | — | 1 | 1 |
| Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | — | — | — | — | 1 | 1 |
| Ascites | D001201 | HP_0001541 | R18 | — | — | — | — | 1 | 1 |
| Esophageal and gastric varices | D004932 | EFO_0009545 | I85 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Albinterferon alfa-2b |
| INN | albinterferon alfa-2b |
| Description | Albinterferon (alb-IFN, trade name Albuferon) is a recombinant fusion protein drug consisting of interferon alpha (IFN-α) linked to human albumin. Conjugation to human albumin prolongs the half-life of the IFN-α to about 6 days, allowing to dose it every two to four weeks.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107842 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 4DVS4AG4DF (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use